Tandem Diabetes Care INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Tandem Diabetes Care, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026, detailing proposals for director elections, executive compensation, and plan amendments.
NASDAQ
DEFA14A: Tandem Diabetes Care Seeks Shareholder Approval for Board Declassification and Auditor Ratification
Tandem Diabetes Care is asking shareholders to vote on key proposals, including declassifying the board structure and ratifying Ernst & Young as the independent auditor.
NASDAQ
DEF 14A: Tandem Diabetes Care Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Tandem Diabetes Care will hold its 2025 Annual Meeting of Stockholders virtually on May 21, 2025, to vote on the election of directors, executive compensation, the frequency of say-on-pay votes, and the ratification of the company's independent auditor.
NASDAQ
Tandem Diabetes Care is asking shareholders to vote on key proposals including declassifying the board structure, increasing shares under employee stock purchase and long-term incentive plans, executive compensation, and ratifying the appointment of Ernst & Young LLP as the independent auditor.
NASDAQ
Tandem Diabetes Care is asking stockholders to approve amendments to its 2013 Employee Stock Purchase Plan and 2023 Long-Term Incentive Plan to increase the number of shares available for issuance.